Tuesday, May 21, 2019 11:26:41 AM
Experts Predict End to Decades-Long Deadlock in Drug Developments
A UC San Francisco-led consortium has received a $26.2 million award from the U.S. Army Medical Materiel Development Activity to develop treatments for traumatic brain injury. The Transforming Research and Clinical Knowledge in Traumatic Brain Injury Network, known as TRACK-TBI NET, will lead clinical trials of phase II drugs tested nationwide in 18 hospitals with Level 1 trauma centers.
“Over the course of decades, there have been more than 30 clinical trials for TBI, but to date no effective drugs have been identified,” said Geoffrey Manley, MD, PhD, principal investigator of TRACK-TBI and professor of neurosurgery in the UCSF Department of Neurological Surgery. “We hope that the new research will prove more fruitful than previous TBI studies that failed to distinguish patients by objective findings obtained from imaging or blood draws.”
The trials will match patients with a treatment according to findings on imaging, such as hemorrhage, brain bruising or neuro-inflammation, as well as the presence of blood-based biomarkers.
There were approximately 2.8 million TBI-associated hospitalizations, visits to emergency departments and deaths in 2013, according to the U.S. Centers for Disease Control and Prevention. Although many patients recover spontaneously from TBIs – which include concussions, regarded as mild TBIs – memory, movement, sensations and emotions may be impacted in the long term.
Earlier this year, UCSF researchers reported links between TBI and dementia, and TBI and Parkinson’s disease.
Awareness of TBI has focused on athletes and those in the armed forces, noted Manley, who is also chief of neurosurgery at Zuckerberg San Francisco General Hospital and Trauma Center, and a member of the UCSF Weill Institute for Neurosciences. In fact, the condition is prevalent across all populations, due to falls and motor vehicle accidents, with the fastest-growing incidence among those over the age of 75.
“We are entering a new era of precision medicine in the research and treatment of TBI,” Manley said. “Using novel and developing tools in the fields of imaging, biomarkers and genomics, we are better able to diagnose patients and test treatments to relieve the substantial burden that patients carry for life.”
TRACK-TBI has built a network of 3,000 patients whose diagnoses cover the spectrum of mild-to-severe TBI, and developed a standardized approach to analyze imaging, clinical data, biospecimens and treatment outcomes across research sites. Additionally, its databases include what may be the world’s largest serial collection of brain scans and biospecimens of TBI patients.
The U.S. Department of Defense award will be administered by the Medical Technology Enterprise Consortium over a five-year period.
LINK: https://www.ucsf.edu/news/2018/10/412001/ucsf-led-consortium-receives-262m-develop-therapies-traumatic-brain-injury
$QRON
Recent QRON News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2023 01:36:38 AM
- Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and TBIs • InvestorsHub NewsWire • 07/25/2023 03:14:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 07:24:55 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM